184 related articles for article (PubMed ID: 26929672)
1. Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis.
Tran JQ; Othman AA; Mikulskis A; Wolstencroft P; Elkins J
Clin Pharmacol; 2016; 8():9-13. PubMed ID: 26929672
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
Diao L; Hang Y; Othman AA; Nestorov I; Tran JQ
Clin Pharmacokinet; 2016 Aug; 55(8):943-55. PubMed ID: 26873229
[TBL] [Abstract][Full Text] [Related]
3. Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials.
Minocha M; Tran JQ; Sheridan JP; Othman AA
Clin Pharmacokinet; 2016 Jan; 55(1):121-30. PubMed ID: 26242380
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.
Othman AA; Tran JQ; Tang MT; Dutta S
Clin Pharmacokinet; 2014 Oct; 53(10):907-18. PubMed ID: 25212703
[TBL] [Abstract][Full Text] [Related]
5. Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
Giovannoni G; Radue EW; Havrdova E; Riester K; Greenberg S; Mehta L; Elkins J
J Neurol; 2014 Feb; 261(2):316-23. PubMed ID: 24375015
[TBL] [Abstract][Full Text] [Related]
6. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.
Radue EW; Sprenger T; Vollmer T; Giovannoni G; Gold R; Havrdova E; Selmaj K; Stefoski D; You X; Elkins J
Eur J Neurol; 2016 Feb; 23(2):412-5. PubMed ID: 26806217
[TBL] [Abstract][Full Text] [Related]
7. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
Gold R; Giovannoni G; Selmaj K; Havrdova E; Montalban X; Radue EW; Stefoski D; Robinson R; Riester K; Rana J; Elkins J; O'Neill G;
Lancet; 2013 Jun; 381(9884):2167-75. PubMed ID: 23562009
[TBL] [Abstract][Full Text] [Related]
8. Population PK-PD analyses of CD25 occupancy, CD56
Diao L; Hang Y; Othman AA; Mehta D; Amaravadi L; Nestorov I; Tran JQ
Br J Clin Pharmacol; 2016 Nov; 82(5):1333-1342. PubMed ID: 27333593
[TBL] [Abstract][Full Text] [Related]
9. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study.
Havrdova E; Giovannoni G; Stefoski D; Forster S; Umans K; Mehta L; Greenberg S; Elkins J
Mult Scler; 2014 Apr; 20(4):464-70. PubMed ID: 24022270
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic protein-drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach.
Tran JQ; Othman AA; Wolstencroft P; Elkins J
Br J Clin Pharmacol; 2016 Jul; 82(1):160-7. PubMed ID: 26991517
[TBL] [Abstract][Full Text] [Related]
11. Daclizumab and its use in multiple sclerosis treatment.
Milo R; Osherov M
Drugs Today (Barc); 2017 Jan; 53(1):7-18. PubMed ID: 28387383
[TBL] [Abstract][Full Text] [Related]
12. Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis.
Preiningerova JL; Vachova M
Ther Adv Neurol Disord; 2017 Jan; 10(1):67-75. PubMed ID: 28450896
[TBL] [Abstract][Full Text] [Related]
13. Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial.
Phillips G; Guo S; Bender R; Havrdová E; Proskorovsky I; Vollmer T
Mult Scler Relat Disord; 2016 Mar; 6():66-72. PubMed ID: 27063626
[TBL] [Abstract][Full Text] [Related]
14. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
Giovannoni G; Gold R; Selmaj K; Havrdova E; Montalban X; Radue EW; Stefoski D; McNeill M; Amaravadi L; Sweetser M; Elkins J; O'Neill G;
Lancet Neurol; 2014 May; 13(5):472-81. PubMed ID: 24656609
[TBL] [Abstract][Full Text] [Related]
15. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Kappos L; Wiendl H; Selmaj K; Arnold DL; Havrdova E; Boyko A; Kaufman M; Rose J; Greenberg S; Sweetser M; Riester K; O'Neill G; Elkins J
N Engl J Med; 2015 Oct; 373(15):1418-28. PubMed ID: 26444729
[TBL] [Abstract][Full Text] [Related]
16. Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis.
Baldassari LE; Rose JW
Neurotherapeutics; 2017 Oct; 14(4):842-858. PubMed ID: 28707278
[TBL] [Abstract][Full Text] [Related]
17. The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax®.
Ganguly B; Balasa B; Efros L; Hinton PR; Hartman S; Thakur A; Xiong JM; Schmidt B; Robinson RR; Sornasse T; Vexler V; Sheridan JP
MAbs; 2016 Oct; 8(7):1417-1424. PubMed ID: 27367933
[TBL] [Abstract][Full Text] [Related]
18. Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis.
Osherov M; Milo R
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1037-1047. PubMed ID: 28803486
[TBL] [Abstract][Full Text] [Related]
19. A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis.
D'Amico E; Messina S; Caserta C; Patti F
Expert Opin Drug Saf; 2015 Jul; 14(7):1157-68. PubMed ID: 25826609
[TBL] [Abstract][Full Text] [Related]
20. CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS.
Elkins J; Sheridan J; Amaravadi L; Riester K; Selmaj K; Bielekova B; Parr E; Giovannoni G
Neurol Neuroimmunol Neuroinflamm; 2015 Apr; 2(2):e65. PubMed ID: 25635261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
